Af­ter hy­per­ten­sion com­peti­tor gets bought, Min­eralys lines up IPO plans

Min­eralys Ther­a­peu­tics has pen­ciled in a $100 mil­lion ini­tial pub­lic of­fer­ing to take its in­ves­ti­ga­tion­al hy­per­ten­sion drug in­to Phase III test­ing.

The Philadel­phia start­up re­leased topline re­sults for its hy­per­ten­sion drug, dubbed MLS-101 or lorun­dro­stat, two months ago, say­ing it met the pri­ma­ry end­point of re­duc­ing sys­tolic blood pres­sure for pa­tients who were on at least two back­ground med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER